Why Abbott (ABT) is a Top Momentum Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
ABT - Abbott Laboratories
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$123.64
DETAILS
HIGH:
$145.00
LOW:
$92.00
MEDIAN:
$121.00
CONSENSUS:
$123.64
UPSIDE:
9.93%
Stock News
AMG National Trust Bank Has $2.86 Million Holdings in Abbott Laboratories $ABT
AMG National Trust Bank decreased its stake in Abbott Laboratories (NYSE: ABT) by 30.6% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 31,489 shares of the healthcare product maker's stock after selling 13,890 shares during the period. AMG National
Abbott (ABT) Stock Sinks As Market Gains: Here's Why
Abbott (ABT) concluded the recent trading session at $111.59, signifying a -2.2% move from its prior day's close.
The FDA Just Gave Abbott a Diabetes First. Is Its Beaten-Down Stock Ready to Wake Up?
Abbott just scored a regulatory first in diabetes care that no rival has matched, yet the stock sits well below where it traded a year ago. The real question is what it will actually take to close that gap.
Abbott's next-generation Amulet 360™ device receives CE Mark to treat people with atrial fibrillation at risk of stroke
Amulet 360 helps seal the left atrial appendage (LAA) of a person's heart, reducing the need for blood-thinning medication Amulet 360 builds upon Abbott's first-generation LAA device with design updates to enhance how the implant conforms to and seals the LAA to help reduce the risk of a stroke Recent clinical trial data show Amulet 360 met benchmarks for safety and effectiveness ABBOTT PARK, Ill., Aug. 27, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, announced today it has received CE Mark for the Amulet 360™ Left Atrial Appendage (LAA) Occluder, a next-generation device designed to reduce risk of stroke in patients with atrial fibrillation (AFib) not caused by a heart valve issue (non-valvular).
Bank of New York Mellon Corp Reduces Stock Holdings in Abbott Laboratories $ABT
Bank of New York Mellon Corp lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 19.7% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 9,991,899 shares of the healthcare product maker's stock after selling 2,450,818 shares during the quarter.
Abbott Laboratories $ABT Shares Acquired by Bank Hapoalim BM
Bank Hapoalim BM boosted its holdings in Abbott Laboratories (NYSE: ABT) by 80.7% in the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 12,765 shares of the healthcare product maker's stock after purchasing an additional 5,699 shares during the
FDA authorizes Abbott's wearable to monitor ketone and glucose in diabetes patients
The U.S. Food and Drug Administration said on Tuesday it authorized Abbott Laboratories' glucose monitor, making it the first device that continuously monitors both ketone levels and blood sugar.
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes PR Newswire
Abbott receives FDA authorization for world's first dual glucose-ketone sensing technology for people with diabetes
Libre Duo 10 Day is a first-of-its-kind, two-in-one biowearable that monitors glucose and helps detect rising ketone levels that can lead to diabetic ketoacidosis (DKA), a serious health condition for people living with diabetes Designed to seamlessly address a critical gap in ketone monitoring, providing needed health data without adding burden on people living with diabetes Integrates with the latest-generation Libre app available in the U.S. and the full Libre digital health ecosystem; designed for compatibility with leading automated insulin delivery (AID) systems ABBOTT PARK, Ill., Aug. 25, 2026 /PRNewswire/ -- Abbott (NYSE: ABT), the global healthcare leader, today announced U.S. Food and Drug Administration (FDA) authorization of its Libre Duo 10 Day system, the world's first dual glucose‑ketone sensing technology.
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now?
ABT edges DXCM on price-target upside and valuation, while both pursue CGM growth through innovation, adoption and strong liquidity.
Gateway Wealth Partners LLC Sells 15,431 Shares of Abbott Laboratories $ABT
Gateway Wealth Partners LLC lessened its stake in shares of Abbott Laboratories (NYSE: ABT) by 64.3% during the undefined quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 8,564 shares of the healthcare product maker's stock after selling 15,431 shares during the quarter. Gateway Wealth
Choreo LLC Sells 4,580 Shares of Abbott Laboratories $ABT
Choreo LLC cut its position in Abbott Laboratories (NYSE: ABT) by 4.4% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 100,143 shares of the healthcare product maker's stock after selling 4,580 shares during the quarter. Choreo LLC's holdings in Abbott Laboratories
Abbott Laboratories $ABT Shares Bought by Golden Reserve Retirement LLC
Golden Reserve Retirement LLC grew its holdings in Abbott Laboratories (NYSE: ABT) by 155.2% in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 9,138 shares of the healthcare product maker's stock after acquiring an additional 5,557 shares during the quarter.
NVST or ABT: Which Is the Better Value Stock Right Now?
Investors interested in Medical - Products stocks are likely familiar with Envista (NVST) and Abbott (ABT). But which of these two stocks presents investors with the better value opportunity right now?
Here's What Is Shaping Abbott's Diagnostics Growth
ABT's Diagnostics growth is being reshaped as weaker respiratory testing offsets healthy routine demand and 13% cancer diagnostics growth.
Billionaire Ken Griffin Just Loaded Up on AbbVie and Abbott. Here's Whether Investors Should Follow His Lead.
AbbVie and Abbott stand out as strong healthcare investments because they combine established businesses with long-term growth opportunities.
ABT DCF Analysis: Intrinsic Value $94 vs Price $117
On August 24, 2026, we delve into the DCF analysis for Abbott Laboratories (ABT), a company currently facing a mixed price performance backdrop. Over the past w
Better Dividend King to Buy Right Now: Abbott Labs or Johnson & Johnson?
Abbott Laboratories has faced challenges, but it should successfully overcome them. Johnson & Johnson is performing well, and there could be more to come ahead.
D.A. Davidson & CO. Sells 38,578 Shares of Abbott Laboratories $ABT
D.A. Davidson and CO. trimmed its stake in shares of Abbott Laboratories (NYSE: ABT) by 20.7% during the undefined quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 148,208 shares of the healthcare product maker's stock after selling 38,578 shares during
Price Targets
Abbott upgraded to Outperform from Peer Perform at Wolfe Research
$130.00
(was $110.92)
Wolfe Research
Abbott price target lowered to $125 from $135 at UBS
$125.00
(was $108.83)
Patrick Wood
·
UBS
Abbott Labs (ABT) Reiterated at Buy by Benchmark After Q2 Model Updates
$120.00
(was $100.67)
Benchmark Co.
Abbott price target raised to $118 from $115 at Piper Sandler
$118.00
(was $98.82)
Piper Sandler
Abbott Labs (ABT) PT Raised to $134 at BTIGMember Login
$134.00
(was $98.82)
BTIG
Abbott price target lowered to $112 from $120 at Evercore ISI
$112.00
(was $93.64)
Vijay Kumar
·
Evercore ISI
Abbott initiated with an Outperform at Baird
$121.00
(was $90.68)
David Rescott
·
Robert W. Baird
Abbott downgraded to Neutral from Outperform at Daiwa
$92.00
(was $92.75)
Daiwa
Abbott price target lowered to $143 from $144 at Barclays
$143.00
(was $96.83)
Matt Miksic
·
Barclays
Abbott price target lowered to $115 from $132 at Oppenheimer
$115.00
(was $95.46)
UBS
Abbott price target lowered to $115 from $135 at Piper Sandler
$115.00
(was $95.46)
Piper Sandler
Abbott price target lowered to $120 from $145 at Stifel
$120.00
(was $95.46)
Stifel Nicolaus
UBS Reiterates Buy Rating on Abbott Labs (ABT) on DD Medical Device Growth Sustainability
$158.00
(was $108.42)
Danielle Antalffy
·
UBS
Abbott Labs (ABT) Reiterated at Buy by Benchmark After FreeDM Trial Results
$145.00
(was $108.14)
New Street
Abbott price target lowered to $142 from $169 at Barclays
$142.00
(was $109.30)
Barclays
Freedom Capital Markets Upgrades Abbott Labs (ABT) to Buy
$120.00
(was $106.09)
Ilya Zubkov
·
Loop Capital Markets
Abbott price target lowered to $138 from $144 at Evercore ISI
$138.00
(was $108.61)
Evercore ISI
Abbott price target lowered to $132 from $140 at Oppenheimer
$132.00
(was $108.60)
UBS
Abbott price target lowered to $125 from $140 at Mizuho
$125.00
(was $108.60)
Anthony Petrone
·
Mizuho Securities
Abbott price target lowered to $135 from $150 at Piper Sandler
$135.00
(was $108.60)
Piper Sandler